
1. lancet infect dis. 2017 feb;17(2):174-183. doi: 10.1016/s1473-3099(16)30415-7.
epub 2016 nov 3.

a surrogate marker piperaquine-resistant plasmodium falciparum malaria: a
phenotype-genotype association study.

witkowski b(1), duru v(2), khim n(1), ross ls(3), saintpierre b(4), beghain j(4),
chy s(2), kim s(2), ke s(2), kloeung n(2), eam r(2), khean c(2), ken m(2), loch
k(2), bouillon a(5), domergue a(2), l(6), bouchier c(6), leang r(7), huy r(7),
nuel g(8), barale jc(5), legrand e(9), ringwald p(10), fidock da(3),
mercereau-puijalon o(4), ariey f(11), ménard d(12).

author information: 
(1)malaria molecular epidemiology unit, institut pasteur cambodia, phnom penh,
cambodia; malaria translational research unit, institut pasteur, paris, france;
institut pasteur cambodia, phnom penh, cambodia.
(2)malaria molecular epidemiology unit, institut pasteur cambodia, phnom penh,
cambodia.
(3)department microbiology immunology division infectious diseases,
department medicine, columbia university medical center, new york, ny, usa.
(4)department parasites insect vectors, institut pasteur, paris, france.
(5)malaria translational research unit, institut pasteur, paris, france; institut
pasteur cambodia, phnom penh, cambodia; structural microbiology unit, biology 
of malaria targets group, department structural biology chemistry and
cnrs, umr3528, institut pasteur, paris, france.
(6)plate-forme génomique, département génomes et génétique, institut pasteur,
paris, france.
(7)national center parasitology, entomology malaria control, phnom penh, 
cambodia.
(8)laboratoire de mathématiques appliquées (map5) umr cnrs 8145, université paris
descartes, paris, france.
(9)malaria translational research unit, institut pasteur, paris, france; institut
pasteur cambodia, phnom penh, cambodia; department parasites insect
vectors, institut pasteur, paris, france.
(10)global malaria programme, world health organization, geneva, switzerland.
(11)department parasites insect vectors, institut pasteur, paris, france; 
institut cochin inserm u1016, université paris-descartes, sorbonne paris cité,
and laboratoire de parasitologie-mycologie, hôpital cochin, paris, france.
(12)malaria molecular epidemiology unit, institut pasteur cambodia, phnom
penh, cambodia; malaria translational research unit, institut pasteur, paris,
france; institut pasteur cambodia, phnom penh, cambodia. electronic address:
dmenard@pasteur-kh.org.

erratum in
    lancet infect dis. 2018 aug;18(8):829.

comment in
    lancet infect dis. 2017 feb;17(2):119-121.

background: western cambodia epicentre plasmodium falciparum multidrug 
resistance facing high rates dihydroartemisinin-piperaquine treatment
failures. genetic tools detect multidrug-resistant parasites needed.
artemisinin resistance tracked using k13 molecular marker, no
marker exists piperaquine resistance. aimed identify genetic markers of
piperaquine resistance study association with
dihydroartemisinin-piperaquine treatment failures.
methods: obtained blood samples cambodian patients infected p
falciparum treated dihydroartemisinin-piperaquine. patients were
followed 42 days years 2009-15. established in-vitro and
ex-vivo susceptibility profiles subset using piperaquine survival assays.
we determined whole-genome sequences illumina paired-reads sequencing, copy
number variations qpcr, rna concentrations qrt-pcr, protein
concentrations immunoblotting. fisher's exact non-parametric wilcoxon
rank-sum tests used identify significant differences single-nucleotide
polymorphisms copy number variants, respectively, differential
distribution piperaquine-resistant piperaquine-sensitive parasite
lines.
findings: whole-genome exon sequence analysis 31 culture-adapted parasite
lines associated amplification plasmepsin 2-plasmepsin 3 gene cluster with
in-vitro piperaquine resistance. ex-vivo piperaquine survival assay profiles of
134 isolates correlated plasmepsin 2 gene copy number. 725 patients
treated dihydroartemisinin-piperaquine, multicopy plasmepsin 2 sample
collected treatment associated adjusted hazard ratio (ahr) for
treatment failure 20·4 (95% ci 9·1-45·5, p<0·0001). multicopy plasmepsin 2
predicted dihydroartemisinin-piperaquine failures 0·94 (95% ci 0·88-0·98)
sensitivity 0·77 (0·74-0·81) specificity. analysis samples collected
across country 2002 2015 showed geographical temporal
increase proportion multicopy plasmepsin 2 parasites highly
correlated increasing dihydroartemisinin-piperaquine treatment failure rates
(r=0·89 [95% ci 0·77-0·95], p<0·0001, spearman's coefficient rank
correlation). dihydroartemisinin-piperaquine efficacy day 42 fell 90%
when proportion multicopy plasmepsin 2 parasites exceeded 22%.
interpretation: piperaquine resistance cambodia strongly associated with
amplification plasmepsin 2-3, encoding haemoglobin-digesting proteases,
regardless location. multicopy plasmepsin 2 constitutes surrogate
molecular marker track piperaquine resistance. molecular toolkit combining
plasmepsin 2 k13 mdr1 monitoring provide timely information for
antimalarial treatment containment policies.
funding: institut pasteur cambodia, institut pasteur paris, national
institutes health, who, agence nationale de la recherche, investissement
d'avenir programme, laboratoire d'excellence integrative "biology emerging
infectious diseases".

copyright open access article published cc 3.0 igo
license permits unrestricted use, distribution, reproduction any
medium, provided original work properly cited. use article,
there suggestion endorses specific organisation,
products services. use logo permitted. notice
should preserved along article’s original url.

doi: 10.1016/s1473-3099(16)30415-7 
pmcid: pmc5266792
pmid: 27818097  [indexed medline]

